On the other hand, the smaller aggregates to which Lecanemab has a much higher affinity, are formed during the earlier stages of AD, during which clearing Aβ is a viable strategy to slow down disease progression and as there is not yet significant neuronal loss, restore cognition.
← all excerpts
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease.
1
—
—